GENFIT

Regulatory Filings • Mar 3, 2014

www.genfit.com

GENFIT-SANOFI COLLABORATION: KEY MILESTONE ACHIEVED WITH SUCCESS

Lille (France), Boston (Massachusetts, United States), March 3, 2014 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the demonstration of the beneficial effects of several molecules in various in vivo models related to the diseases targeted in its research collaboration with Sanofi.

The achievement of this new key milestone, after those achieved in April 2012 and January 2013, comes within the co-research contract signed between the two Companies in March 2011. In this partnership, GENFIT collaborates with Sanofi to develop new medicines to correct the mitochondrial dysfunction associated with certain metabolic disorders, in particular Type 2 diabetes. Indeed, the mitochondria acts as the "power-house" of the cell, and a reduction in its oxidative function or its energy-producing capacity disturbs insulin signaling pathways, favorizing the development of the insulin resistance that characterizes the diabetic state. Targeting mitochondrial dysfunction therefore represents an innovative approach to the treatment of diabetic patients.

In accordance with the terms of the contract, whereby Sanofi obtained the exclusive worldwide rights to develop and commercialize the molecules arising from the research collaboration, GENFIT has received the third of the milestone payments included in the collaboration and licensing agreement. Depending on the preclinical and clinical development, and the subsequent registration and commercialization of resulting products, the total of GENFIT's milestone payments included in the agreement could reach \$54 million (€39 million), in addition to royalties from future sales of products developed by Sanofi and resulting from the collaboration.

Dr. Raphaël Darteil, Director of Scientific Operations at GENFIT, declared: « Following the pharmacological evaluation performed during 2013 in different animal models, including mouse models of Type 2 diabetes, several molecules developed in the course of our collaboration with Sanofi have shown very promising beneficial effects. These results should soon enable us to identify a candidate molecule for preclinical development. »

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, added: «We are delighted that, after three years of fruitful collaboration, all the key milestones have been successfully met within the projected timelines. The appropriate sharing of research activities between our two companies, founded on mutual understanding and trust resulting from more than 10 years of collaboration, benefits this collaboration and raises expectations of future success. »

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT Jean-François Mouney – CEO & Chairman of the Management Board Ph. +333 2016 4000

MILESTONES – Press Relations Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr